Magdalena Dryglewska
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Magdalena Dryglewska has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Maria Majdan
Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland
3 shared publications - Bożena Targońska-Stępniak
Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland
1 shared publication - Dominika Szlichta
Toxicology Clinic, Medical University, Lublin, Poland
1 shared publication - Elżbieta Kimak
Department of Laboratory Diagnostics, Medical University, Lublin, Poland
1 shared publication - Ewa Wielosz
Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland
1 shared publication - Ewa Łyś-Toporowska1 shared publication
Latest Publications
- Open Access
- 14 July 2026
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 64 (3) , 174-180
Changes in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study
Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory disease that can be managed with tumor necrosis factor (TNF) inhibitors. This study evaluated the effects of adalimumab, a TNF inhibitor, on inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Monitoring disease activity during therapy is important for assessing treatment response. Material and methods: We analyzed the medical history of 28 patients with confirmed AS, treated with adalimumab. The inflammatory markers neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), CRP, ESR, and the Bath Ankylosing Spondylitis Disease Activity Index were assessed at the beginning of the observation (month 0) and after 3, 6, and 12 months of therapy. Results: The mean NLR value after 3 months of treatment was 1.48 (95% confidence interval, CI: 0.92–2.03, p < 0.001), after 6 months was 1.48 (95% CI: 0.92–2.12, p < 0.001), and after 12 months was 1.67 (95% CI: 1.08–2.30, p < 0.001). Mean MLR value after 3 months of treatment was 0.07 (95% CI: 0.03–0.13, p = 0.005), after 6 months was 0.05 (95% CI: 0.00–0.11, p = 0.101), and after 12 months was 0.06 (95% CI: 0.01–0.11, p = 0.047), showing statistical significance only after 3 and 12 months. The mean PLR value after 3 months of treatment was 52.8 (95% CI: 30.1–79.60, p < 0.001), after 6 months was 65.50 (95% CI: 31.60–83.90, p < 0.001), and after 12 months was 68.80 (95% CI: 42.70–93.70, p < 0.001). Conclusions: Neutrophil–lymphocyte ratio may be a useful marker of inflammation in patients with AS. Monocyte–lymphocyte ratio and PLR require further investigation. Peripheral blood tests are simple and inexpensive to perform, making hematological markers promising tools for monitoring inflammatory diseases.
- 14 July 2026
- Published by Termedia Sp. z.o.o. in Rheumatology
- Vol. 64 (3) , 174-180
Open AccessChanges in hematological indices during adalimumab therapy in ankylosing spondylitis: a one-year retrospective study
Introduction: Ankylosing spondylitis (AS) is a chronic inflammatory disease that can be managed with tumor necrosis factor (TNF) inhibitors. This study evaluated the effects of adalimumab, a TNF inhibitor, on inflammatory markers, including C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR). Monitoring disease activity during therapy is important for assessing treatment response. Material and methods: We analyzed the medical history of 28 patients with confirmed AS, treated with adalimumab. The inflammatory markers neutrophil–lymphocyte ratio (NLR), platelet–lymphocyte ratio (PLR), monocyte–lymphocyte ratio (MLR), CRP, ESR, and the Bath Ankylosing Spondylitis Disease Activity Index were assessed at the beginning of the observation (month 0) and after 3, 6, and 12 months of therapy. Results: The mean NLR value after 3 months of treatment was 1.48 (95% confidence interval, CI: 0.92–2.03, p < 0.001), after 6 months was 1.48 (95% CI: 0.92–2.12, p < 0.001), and after 12 months was 1.67 (95% CI: 1.08–2.30, p < 0.001). Mean MLR value after 3 months of treatment was 0.07 (95% CI: 0.03–0.13, p = 0.005), after 6 months was 0.05 (95% CI: 0.00–0.11, p = 0.101), and after 12 months was 0.06 (95% CI: 0.01–0.11, p = 0.047), showing statistical significance only after 3 and 12 months. The mean PLR value after 3 months of treatment was 52.8 (95% CI: 30.1–79.60, p < 0.001), after 6 months was 65.50 (95% CI: 31.60–83.90, p < 0.001), and after 12 months was 68.80 (95% CI: 42.70–93.70, p < 0.001). Conclusions: Neutrophil–lymphocyte ratio may be a useful marker of inflammation in patients with AS. Monocyte–lymphocyte ratio and PLR require further investigation. Peripheral blood tests are simple and inexpensive to perform, making hematological markers promising tools for monitoring inflammatory diseases.
- Open Access
- 28 September 2020
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 28 (1) , 189-192
The prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis
Introduction: Anti-PM/Scl (a-PM/Scl) antibodies are found in different systemic autoimmune diseases such as polymyositis, dermatomyositis, systemic sclerosis (SSc) and overlap syndromes. According to literature, they are detected in approx. 2% of SSc patients, but their presence is more common...
- 28 September 2020
- Published by Institute of Rural Health in Annals of Agricultural and Environmental Medicine
- Vol. 28 (1) , 189-192
Open AccessThe prevalence and significance of anti-PM/Scl antibodies in systemic sclerosis
Introduction: Anti-PM/Scl (a-PM/Scl) antibodies are found in different systemic autoimmune diseases such as polymyositis, dermatomyositis, systemic sclerosis (SSc) and overlap syndromes. According to literature, they are detected in approx. 2% of SSc patients, but their presence is more common...
- Open Access
- 1 June 2008
- Published by Walter de Gruyter GmbH in Annales UMCS, Medicina
- Vol. 63 (1) , 51-55
Effects of leflunomide therapy on the serum lipid profile in patients with rheumatoid arthritis
- 1 June 2008
- Published by Walter de Gruyter GmbH in Annales UMCS, Medicina
- Vol. 63 (1) , 51-55
Open AccessEffects of leflunomide therapy on the serum lipid profile in patients with rheumatoid arthritis